MARTINSRIED/Munich, Germany and WALTHAM, Mass. and PRINCETON, N.J., April 27 /PRNewswire-FirstCall/ -- GPC Biotech AG today announced that it will hold a conference call on May 4, 2006 to discuss its financial results for the first quarter of 2006 and provide an update on the Company’s business. The results will be published on May 4 in advance of the conference call.
Participants may listen via live webcast, accessible through the GPC Biotech Web site at www.gpc-biotech.com or via telephone. A replay will be available via the Web site following the live event. The call, which will be conducted in English, will be held on May 4 at 14:30 CET/8:30 AM EDT.
The dial-in numbers for the call are as follows: European participants: 0049 (0)69 500 71846 U.S. participants: 1-866-770-7146 (toll-free) Please dial in 10 minutes before the beginning of the meeting.
GPC Biotech AG is a biopharmaceutical company discovering and developing new anticancer drugs. The Company’s lead product candidate - satraplatin - has achieved target enrollment in a Phase 3 registrational trial as a second-line chemotherapy treatment in hormone-refractory prostate cancer. The U.S. FDA has granted fast track designation to satraplatin for this indication, and GPC Biotech has begun the rolling NDA submission process for this compound. GPC Biotech is also developing a monoclonal antibody with a novel mechanism-of- action against a variety of lymphoid tumors, currently in Phase 1 clinical development, and has ongoing drug development and discovery programs that leverage its expertise in kinase inhibitors. GPC Biotech AG is headquartered in Martinsried/Munich (Germany). The Company’s wholly owned U.S. subsidiary has sites in Waltham, Massachusetts and Princeton, New Jersey. For additional information, please visit the Company’s Web site at www.gpc-biotech.com.
For further information, please contact: GPC Biotech AG Martin Braendle Associate Director, Investor Relations & Corporate Communications Phone: +49 (0)89 8565-2693 ir@gpc-biotech.com In the U.S.: Laurie Doyle Associate Director, Investor Relations & Corporate Communications Phone: +1 781-890-9007 X267 usinvestors@gpc-biotech.com
GPC Biotech AG
CONTACT: Martin Braendle, Associate Director, Investor Relations &Corporate Communications of GPC Biotech AG, Phone: +49 (0)89 8565-2693, orir@gpc-biotech.com; or In the U.S.: Laurie Doyle, Associate Director,Investor Relations & Corporate Communications, Phone: +1 781-890-9007 X267,or usinvestors@gpc-biotech.com
Web site: http://www.gpc-biotech.com/
